Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.5.0.2
Note 3 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Biotechnology [Member] | Operating Segments [Member]    
Net sales $ 86,787 $ 75,743
Operating income 42,480 39,316
Diagnostics [Member] | Operating Segments [Member]    
Net sales 24,233 20,362
Operating income 6,303 4,711
Protein Platforms [Member] | Operating Segments [Member]    
Net sales 19,573 16,296
Operating income 209 (1,172)
Operating Segments [Member]    
Operating income 48,992 42,855
Intersegment Eliminations [Member]    
Net sales (12) (20)
Corporate, Non-Segment [Member]    
Corporate general and administrative (1,582) (965)
Acquisition Related [Member]    
Amortization expense (10,188) (7,411)
Net sales 130,581 112,381
Operating income 25,442 31,028
Cost recognized on sale of acquired inventory (4,219) (1,113)
Amortization expense (10,188)  
Acquisition related expenses (4,369) (301)
Stock-based compensation (3,176) (2,038)
Corporate general and administrative $ (46,263) $ (33,040)